dilutional coagulopathy
Conditions
Interventions
Group 1: study arm 1 - fibrinogen
After 20%, respectively 40%, in-vitro-dilution of blood samples with crystalloids, the dilutional coagulopathy will be either treated with fibrinogen or fibrinogen c
Sponsors
Justus-Liebig-Universität Gießen Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - age > 18 years - patentes informed consent - no severe diseases in patients history (malignancies, cardiovascular and respiratory disorders) - pat. should feel fine before blood donation - no coagulatory disorders in patients history
Exclusion criteria
Exclusion criteria: - exclusion criteria in accordance to the general exclusion criteria for blood donation of the clinic for transfusion medicine - need for anticoagulative medication
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Difference of activity of the coagulatory factors (Fibrinogen, V, VIII, XI) as well as of the Clotting Time und Mean Clot Firmness Time after thawing. | — |
Primary
| Measure | Time frame |
|---|---|
| Difference of Clotting Time and Mean Clot Firmness time after treatment of the dilutional coagulopathy | — |
Countries
Germany
Contacts
Public ContactEmmanuel Schneck
Universitätsklinikum Gießen und Marburg, Standort Gießen Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie
Outcome results
None listed